BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12879789)

  • 1. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meglitinide analogues for type 2 diabetes mellitus.
    Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
    Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
    Guay DR
    Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypersensitivity to repaglinide.
    Rojas P; Sánchez L; Santos A; Góõmez MP; Blanco H; Laguna JJ
    J Investig Allergol Clin Immunol; 2011; 21(3):245-7. PubMed ID: 21548456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
    Baron MA
    Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
    [No Abstract]   [Full Text] [Related]  

  • 10. Nateglinide (Starlix): update on a new antidiabetic agent.
    Phillips LS; Dunning BE
    Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
    Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
    Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
    Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
    Twaites B; Wilton LV; Layton D; Shakir SA
    Acta Diabetol; 2007 Dec; 44(4):233-9. PubMed ID: 17874223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
    Li C; Xia J; Zhang G; Wang S; Wang L
    Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.